Aspen Neuroscience secures Series C to advance ANPD001

Aspen Neuroscience, a San Diego-based clinical-stage biotech focused on autologous regenerative therapies, has closed a substantial $115M Series C round. The financing is aimed at accelerating the company’s lead program, ANPD001, in the quest to address moderate to severe Parkinson’s disease using patient-derived iPSC technology. The round underscores the ongoing appetite for advanced cell therapies in neurology and signals continued momentum in autologous approaches that blend precision biology with scalable manufacturing.

The syndicate is led by a powerhouse group of investors, including OrbiMed, ARCH Venture Partners, Frazier Life Sciences, and Revelation Partners. They are joined by existing backers such as Medical Excellence Capital, S32, Axon Ventures, LYFE Capital, and LifeForce Capital, highlighting a broad base of specialist biotech and health-tech participants willing to back bold, translational programs at this stage of development. The round also drew new entrants, underscoring the strategic interest in in-house autologous platforms capable of addressing neurodegenerative burdens.

ANPD001 sits at the heart of Aspen’s pipeline as a potential disease-modifying strategy, leveraging the company’s autologous iPSC platform to generate patient-matched neural cells. The proceeds will support ongoing optimization of the product candidate, expand clinical development activities, and fund process and manufacturing scale-up to prepare for potential later-stage trials. In addition to advancing ANPD001, Aspen is exploring expansion into other neurodegenerative indications where patient-specific cell therapies could offer meaningful clinical gains.

Beyond the program itself, the funding climate for biotech and regenerative medicine remains robust, with investors increasingly favoring platforms that combine strong science with scalable manufacturing footprints. The deal follows a recent wave of private capital into cell and gene therapy, where co-led rounds and multinational syndicates have become common as teams de-risk early science and push toward proof-of-concept data readouts. The impact of public–private support, including grant programs like California’s CIRM, continues to complement private funding, helping de-risk translational milestones and accelerate clinical timelines.

For Aspen, the capital infusion comes at a pivotal moment as the company seeks to broaden patient access to regenerative therapies while building out a robust platform for future programs. Management has signaled a disciplined plan to advance ANPD001 through pivotal milestones while maintaining a pathway to scalable manufacturing and regulatory readiness. With a diversified investor base, Aspen also gains access to a broad network of strategic resources and domain expertise, which should enhance clinical execution and potential partnerships as the program moves forward.